Key opinion leaders weigh in on Novo's CagriSema, with side effect and tolerability results framed as the deciding factor for the drug.
Recap by typeshit. Full story at FirstWord Pharma.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
An indirect comparison found 1.46 points more weight loss than 25 mg Rybelsus at 52 weeks. GlobalData's analyst says head-to-head trials are still needed.
In a 39-person randomized pilot, people on the support programs regained about 3.6% of body weight in four months, versus roughly 11% with usual care.
Loading…